Tech Center 1600 • Art Units: 1633 1636 1657
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18842179 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18555584 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17925125 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION, AND METHODS OF USING THE SAME FOR TREATING COVID-19 | Non-Final OA | ModernaTX, Inc. |
| 17925114 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION | Non-Final OA | ModernaTX, Inc. |
| 18289530 | COMPOSITION FOR PROMOTING ANGIOGENESIS COMPRISING EXTRACELLULAR VESICLES DERIVED FROM THREE-DIMENSIONAL SPHEROID-TYPE CELL AGGREGATE | Non-Final OA | S&E Bio Co., Ltd. |
| 18264923 | USE OF TRANSDIFFERENTIATION OF GLIAL CELLS INTO NEURONS IN PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH NEURON LOSS-OF-FUNCTION OR DEATH | Non-Final OA | SHANGHAI GENEMAGIC BIOSCIENCES CO., LTD. |
| 18276559 | SIGNAL PEPTIDES FOR INCREASED PROTEIN SECRETION | Non-Final OA | LONZA LTD |
| 18041199 | GENE THERAPIES FOR NEURODEGENERATIVE DISORDERS | Non-Final OA | Prevail Therapeutics, Inc. |
| 18197670 | USE OF LEUKEMIA-DERIVED CELLS FOR ENHANCING NATURAL KILLER (NK) CELL THERAPY | Non-Final OA | Mendus B.V. |
| 17997939 | LENTIVIRAL VECTOR MANUFACTURING PROCESS IN PACKED BED BIOREACTOR | Non-Final OA | AGC BIOLOGICS S.P.A. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy